Cover Image
Market Research Report

Investigation Report on China's Entecavir Market, 2018-2022

Published by China Research and Intelligence Product code 762938
Published Content info 30 Pages
Delivery time: 1-2 business days
Price
Back to Top
Investigation Report on China's Entecavir Market, 2018-2022
Published: January 1, 2019 Content info: 30 Pages
Description

In China, more than 100 billion people are chronically infected with hepatitis B virus (HBV), of which 20 million to 30 million have chronic hepatitis B. It is estimated that every year, more than 500,000 people in China die of the liver damage or liver cancer caused by chronic hepatitis B, which leads to losses of over CNY 100 billion.

Developed by Bristol-Myers Squibb, Entecavir is a nucleoside analogue taken by mouth. In Mar. 2005, Entecavir was approved by the FDA. Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir was launched in China at the beginning of 2006 after being approved by the China Food and Drug Administration (CFDA) at the end of 2005. Later, Chinese pharmaceutical companies launched generic Entecavir successively, which drove the growth of the market.

According to CRI's market research, the annual sales value of Entecavir increased from over CNY 30 million in 2006 to CNY 2.03 billion in 2016, and decreased slightly in 2017. Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir still dominates the market. Its market share by sales value reached about 40% in 2017 but is shrinking as impacted by China-made generic drugs.

Entecavir has better and faster antiviral effect and see less side effects and drug resistance than traditional nucleoside analogs. Having a high genetic barrier to resistance, it is a powerful and long-acting HBV inhibitor for early monotherapy. As the demand for new anti-HBV drugs is far from being met, China's Entecavir market is promising with rising sales value in the coming years.

Topics Covered:

  • Development environment of China's Entecavir market
  • Size of China's Entecavir market
  • Competitive landscape of China's Entecavir market
  • Prices of Entecavir in China
  • Major factors influencing the development of China's Entecavir market
  • Prospect of China's Entecavir market
Table of Contents
Product Code: 1901366

Table of Contents

1 Relevant Concepts of Entecavir

  • 1.1 Indications for Entecavir
  • 1.2 Development History of Entecavir in China
  • 1.3 Governmental Approval for Entecavir in China

2 Sales of Entecavir in China, 2013-2017

  • 2.1 Sales Value of Entecavir
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Entecavir
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Entecavir by Dosage Form in China, 2013-2017
    • 2.3.1 Entecavir Capsules
    • 2.3.2 Entecavir Tablets

3 Analysis on Major Entecavir Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Entecavir Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China
  • 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China
  • 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd.
  • 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd.
  • 3.6 Fujian Cosunter Pharmaceutical Co., Ltd.

4 Prices of Entecavir in China, 2017-2018

  • 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong)
  • 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude)
  • 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)
  • 4.4 Suzhou Dawnrays Pharmaceutical Co., Ltd. (Leiyide)
  • 4.5 Fujian Cosunter Pharmaceutical Co., Ltd. (Enganding)

5 Prospect of China's Entecavir Market, 2018-2022

  • 5.1 Factors Influencing Development of China's Entecavir Market
  • 5.2 Forecast on Size of China's Entecavir Market
  • 5.3 Forecast on Trend of China's Entecavir Market

Selected Charts

  • Chart Governmental Approval for Entecavir in China
  • Chart Sales of Entecavir in China, 2013-2017
  • Chart Sales Value of Entecavir in Parts of China, 2013-2017
  • Chart Sales Volume of Entecavir in China, 2013-2017
  • Chart Sales Volume of Entecavir in Parts of China, 2013-2017
  • Chart Sales Value of Entecavir Capsules in China, 2013-2017
  • Chart Sales Volume of Entecavir Capsules in China, 2013-2017
  • Chart Sales Value of Entecavir Tablets in China, 2013-2017
  • Chart Market Share of Top 5 Entecavir Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Entecavir Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir, 2013-2017
  • Chart Sales Volume of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir, 2013-2017
  • Chart Sales Value of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir, 2013-2017
  • Chart Sales Value of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017
  • Chart Sales Value of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017
  • Chart Sales Value of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017
  • Chart Prices of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir (Runzhong) in Parts of China, 2017-2018
  • Chart Prices of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir (Baraclude) in Parts of China in 2017
  • Chart Prices of Jiangxi Qingfeng Pharmaceutical Co., Ltd. 's Entecavir (Weiliqing) in Parts of China in 2017
  • Chart Prices of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir (Leiyide) in Parts of China in 2017
  • Chart Prices of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir (Enganding) in Parts of China in 2017
  • Chart Forecast on Sales Value of Entecavir in China, 2018-2022
Back to Top